{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:18Z","timestamp":1792511538176,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Acute respiratory viral infections (ARVI) are the most common illnesses worldwide. In some instances, mild cases of ARVI progress to hyperinflammatory responses, which are damaging to pulmonary tissue and requiring intensive care. Here we summarize available information on preclinical and clinical effects of XC221GI (1-[2-(1-methyl imidazole-4-yl)-ethyl]perhydroazin-2,6-dione), an oral drug with a favorable safety profile that has been tested in animal models of influenza, respiratory syncytial virus, highly pathogenic coronavirus strains and other acute viral upper respiratory infections. XC221GI is capable of controlling IFN-gamma-driven inflammation as it is evident from the suppression of the production of soluble cytokines and chemokines, including IL-6, IL-8, CXCL10, CXCL9 and CXCL11 as well as a decrease in migration of neutrophils into the pulmonary tissue. An excellent safety profile of XC221GI, which is not metabolized by the liver, and its significant anti-inflammatory effects indicate utility of this compound in abating conversion of ambulatory cases of respiratory infections into the cases with aggravated presentation that require hospitalization. This drug is especially useful when rapid molecular assays determining viral species are impractical, or when direct antiviral drugs are not available. Moreover, XC221GI may be combined with direct antiviral drugs to enhance their therapeutic effects.<\/jats:p>","DOI":"10.3389\/fphar.2023.1087850","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T01:56:46Z","timestamp":1683251806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Curtailing virus-induced inflammation in respiratory infections: emerging strategies for therapeutic interventions"],"prefix":"10.3389","volume":"14","author":[{"given":"Alexander A.","family":"Globenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady V.","family":"Kuzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia V.","family":"Rydlovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I.","family":"Isaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta N.","family":"Vetrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tat\u2019yana N.","family":"Pritchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ancha","family":"Baranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir E.","family":"Nebolsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B79","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3390\/v14112540","article-title":"Oral antiviral treatment for COVID-19: A comprehensive review on Nirmatrelvir\/Ritonavir","volume":"14","author":"Akinosoglou","year":"2022","journal-title":"Viruses"},{"key":"B1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1089\/jir.2010.0131","article-title":"Host response cytokine signatures in viral and nonviral acute exacerbations of chronic obstructive pulmonary disease","volume":"31","author":"Almansa","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e00925","DOI":"10.1002\/prp2.925","article-title":"Nonsteroidal anti-inflammatory drugs in acute viral respiratory tract infections: An updated systematic review","volume":"10","author":"Azh","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jaip.2019.08.043","article-title":"Rhinovirus type in severe bronchiolitis and the development of asthma","volume":"8","author":"Bergroth","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B5","volume-title":"Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2022"},{"key":"B83","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4172\/jaa.1000093","article-title":"Modeling human respiratory viral infections in the cotton rat (Sigmodon hispidus)","volume":"6","author":"Blanco","year":"2014","journal-title":"J. Antivir. Antiretrovir."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2040206618770518","DOI":"10.1177\/2040206618770518","article-title":"Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus","volume":"26","author":"Boukhvalova","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/pr.2012.163","article-title":"CD4+ T-cell counts and interleukin-8 and CCL-5 plasma concentrations discriminate disease severity in children with RSV infection","volume":"73","author":"Brand","year":"2013","journal-title":"Pediatr. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41590-020-0779-1","article-title":"The dynamic changes in cytokine responses in COVID-19: A snapshot of the current state of knowledge","volume":"21","author":"Buszko","year":"2020","journal-title":"Nat. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/v13061062","article-title":"The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner","volume":"13","author":"Callahan","year":"2021","journal-title":"Viruses"},{"key":"B9","doi-asserted-by":"crossref","unstructured":"Respiratory syncytial virus infection (RSV)2022","DOI":"10.1002\/cca.3941"},{"key":"B10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12879-020-05322-x","article-title":"The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: A multicenter, retrospective study","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e140267","DOI":"10.1172\/jci.insight.140267","article-title":"TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs","volume":"6","author":"Deliyannis","year":"2021","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.26442\/00403660.2022.07.201729","article-title":"New opportunities for preventive anti-inflammatory therapy in the management of patients with moderate and severe COVID-19","volume":"94","author":"Gorelov","year":"2022","journal-title":"Ther. Arch."},{"key":"B84","doi-asserted-by":"publisher","first-page":"40","DOI":"10.24875\/AIDSRev.200001261","article-title":"The importance of understanding the stages of COVID-19 in treatment and trials","volume":"23","author":"Griffin","year":"2021","journal-title":"AIDS Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.1208421","article-title":"Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection","volume":"334","author":"Harker","year":"2011","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8053","DOI":"10.4049\/jimmunol.181.11.8053","article-title":"Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases","volume":"181","author":"Hartl","year":"2008","journal-title":"J. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jcv.2017.03.003","article-title":"Serum IFN-\u03b3-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults","volume":"90","author":"Hayney","year":"2017","journal-title":"J. Clin. Virol."},{"key":"B20","unstructured":"Nervtag: Antiviral drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19\n            HorbyP.\n            BarclayW.\n            HiscoxJ.\n            ChandM.\n            BreuerJ.\n            SherwoodE.\n          2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1164\/rccm.201203-0508OC","article-title":"CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin","volume":"187","author":"Ichikawa","year":"2013","journal-title":"Am. J.Respir. Crit. Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1086\/386372","article-title":"Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice","volume":"189","author":"Jafri","year":"2004","journal-title":"J. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. Adults","volume":"373","author":"Jain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41375-020-01085-1","article-title":"IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells","volume":"35","author":"Jiang","year":"2021","journal-title":"Leukemia"},{"key":"B26","unstructured":"COVID-19 dashboard2022"},{"key":"B78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/2589977514666220527105158","article-title":"Molnupiravir in COVID-19: A scoping review","author":"Kaore","year":"2022","journal-title":"Curr Drug Res Rev."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.16.435700","article-title":"SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-\u03baB pathway","author":"Khan","year":"2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0261411","DOI":"10.1371\/journal.pone.0261411","article-title":"Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia","volume":"16","author":"Kositpantawong","year":"2021","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/infdis\/jix648","article-title":"Antiviral response in the nasopharynx identifies patients with respiratory virus infection","volume":"217","author":"Landry","year":"2018","journal-title":"J. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"CD010406","DOI":"10.1002\/14651858.CD010406.pub3","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"2","author":"Lansbury","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/cid\/ciy837","article-title":"The clinical utility of point-of-care tests for influenza in ambulatory care: A systematic review and meta-analysis","volume":"69","author":"Lee","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"E439","DOI":"10.1503\/cmaj.201748","article-title":"Burden of noninfluenza respiratory viral infections in adults admitted to hospital: Analysis of a multiyear Canadian surveillance cohort from 2 centres","volume":"193","author":"Lee","year":"2021","journal-title":"CMAJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"794092","DOI":"10.3389\/fcvm.2022.794092","article-title":"Meta-analysis and systematic review of coagulation disbalances in COVID-19: 41 studies and 17,601 patients","volume":"9","author":"Len","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1016\/j.vaccine.2020.09.048","article-title":"The disease burden of influenza beyond respiratory illness","volume":"39","author":"Macias","year":"2021","journal-title":"Vaccine"},{"key":"B39","first-page":"107","article-title":"Ingavirin might be a promising agent to combat Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2)","volume":"69","author":"Mal\u00edk","year":"2020","journal-title":"Ceska Slov. Farm"},{"key":"B40","doi-asserted-by":"publisher","first-page":"749657","DOI":"10.3389\/fmed.2021.749657","article-title":"Impact of the addition of baricitinib to standard of care including tocilizumab and corticosteroids on mortality and safety in severe COVID-19","volume":"8","author":"Masi\u00e1","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.7883\/yoken.67.392","article-title":"Alteration in serum levels of inflammatory cytokines during parainfluenza virus type 1 infection in patients with severe multiple disabilities","volume":"67","author":"Matsuda","year":"2014","journal-title":"Jpn. J. Infect. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fped.2016.00128","article-title":"Viral infection in the development and progression of pediatric acute respiratory distress syndrome","volume":"4","author":"Nye","year":"2016","journal-title":"Front. Pediatr."},{"key":"B49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.12488","article-title":"A pilot study on reparixin, a CXCR1\/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery","volume":"180","author":"Opfermann","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.7326\/L20-1285","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection","volume":"174","author":"Oran","year":"2021","journal-title":"Ann. Intern Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40121-016-0137-7","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease","volume":"5","author":"Paes","year":"2016","journal-title":"Infect. Dis. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"020421","DOI":"10.7189\/jogh.09.020421","article-title":"Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project","volume":"9","author":"Paget","year":"2019","journal-title":"J. Glob. Health"},{"key":"B53","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","article-title":"Influenza","volume":"390","author":"Paules","year":"2017","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1055\/s-0036-1584801","article-title":"Human influenza virus infections","volume":"37","author":"Peteranderl","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"117839","DOI":"10.1016\/j.lfs.2020.117839","article-title":"Coronaviruses pathogenesis, comorbidities and multi-organ damage \u2013 a review","volume":"255","author":"Renu","year":"2020","journal-title":"Life Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","article-title":"The biology of chemokines and their receptors","volume":"18","author":"Rossi","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"109102","DOI":"10.1016\/j.steroids.2022.109102","article-title":"Corticosteroids: A boon or bane for COVID-19 patients?","volume":"188","author":"Sen","year":"2022","journal-title":"Steroids"},{"key":"B60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201ccytokine storm\u201d relevant to COVID-19?","volume":"180","author":"Sinha","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.18527\/2500-2236-2022-9-1-56-70","article-title":"<em&gt;in vitro&lt;\/em&gt; and <em&gt;in vivo&lt;\/em&gt; pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract","volume":"9","author":"Stukova","year":"2022","journal-title":"Microbiol. Indep. Res. J. (MIR J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"200","DOI":"10.17816\/EID108910","article-title":"Toxicity profile of the new compound XC221GI from pre-clinical studies","volume":"26","author":"Suhanova","year":"2021","journal-title":"Epidemiol. Infect. Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1097\/INF.0b013e3182a14407","article-title":"Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection","volume":"32","author":"Tabarani","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B67","unstructured":"MSD manual professional version. Overview of viral respiratory infections\n            TesiniB.\n          2022"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/antibiotics11081058","article-title":"Outpatient antibiotic and antiviral utilization patterns in patients tested for respiratory pathogens in the United States: A real-world database study","volume":"11","author":"Tse","year":"2022","journal-title":"Antibiot. (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0140-6736(22)00372-5","article-title":"The global COVID-19 treatment divide","volume":"399","author":"Usher","year":"2022","journal-title":"Lancet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"n2663","DOI":"10.1136\/bmj.n2663","article-title":"Buyer beware: Molnupiravir may damage DNA","volume":"375","author":"van Schalkwyk","year":"2021","journal-title":"BMJ"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20200678","article-title":"The many faces of the anti-COVID immune response","volume":"217","author":"Vardhana","year":"2020","journal-title":"J. Exp. Med."},{"key":"B81","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/B978-1-4557-4801-3.00160-0","volume-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","author":"Walsh","year":"2015"},{"key":"B73","doi-asserted-by":"publisher","first-page":"791163","DOI":"10.3389\/fmed.2021.791163","article-title":"Acute respiratory distress syndrome caused by human adenovirus in adults: A prospective observational study in guangdong, China","volume":"8","author":"Wu","year":"2022","journal-title":"Front. Med. (Lausanne)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1087850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T01:56:52Z","timestamp":1683251812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1087850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":65,"alternative-id":["10.3389\/fphar.2023.1087850"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1087850","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1087850"}}